NEW YORK, Jan 30, 2026, 15:18 EST — Regular session
Danaher (DHR) shares ticked up 0.1% to $219.83 Friday afternoon, bouncing back after a sharp slide earlier this week. The stock swung between $217.60 and $221.00 throughout the session.
Still, investors are cautious about the company’s 2026 outlook following two consecutive days of declines. Danaher fell 4.76% on Wednesday and slipped another 2.19% Thursday, with trading volumes hitting around 7.8 million and 7.5 million shares respectively.
This goes beyond just one earnings report. The Washington, D.C.-based company provides a window into lab spending and diagnostic demand, with its forecast shaping expectations for other tools makers during earnings season. Danaher forecast adjusted 2026 earnings between $8.35 and $8.50 per share, matching the $8.42 per share consensus from LSEG analysts. The firm pointed to improving conditions in the pharma market and less policy uncertainty, even as funding for academic research remains weak.
Chief executive Rainer Blair said the company “delivered a strong finish to the year,” pointing to robust gains in bioprocessing and a pickup in diagnostics and life sciences. Danaher reported fourth-quarter revenue of $6.84 billion and an adjusted EPS of $2.23. PR Newswire
Danaher revealed in an 8-K filing that it expects total-company core sales—adjusted for currency and acquisition or divestiture effects—to rise in the low single digits this March quarter. Looking ahead, the company projects growth between 3% and 6% for 2026. Their segment outlook calls for high-single-digit core sales growth in biotech during Q1. Life sciences are forecasted to remain flat or decline slightly, while diagnostics could drop by low single digits before rebounding to low-single-digit growth across the full year.
Life-science tools stocks painted a mixed picture on Friday. Thermo Fisher Scientific dropped around 2.6%, Waters Corporation fell about 1.4%, while Agilent Technologies eked out a small gain.
Thermo Fisher warned that weaker demand tied to U.S. academic research funding could drag on through 2026. CEO Mark Casper told analysts the company expects “a level of customer caution” that should ease later in the year. Reuters
A Schedule 13G/A filed Friday shows The Vanguard Group owns 60.97 million shares of Danaher, an 8.63% stake as of Dec. 31.
Yet challenges loom. Danaher’s earnings report highlighted threats from tariffs, currency swings, and shifts in laws or policies. Added to that are wider economic and geopolitical risks that could throw off its goals.
Traders are bracing for the January U.S. jobs report due Feb. 6, a key data point that might rattle rate expectations and risk sentiment. Danaher is under the microscope as investors look for fresh insights into pharma and biotech spending, plus demand trends in China. Several healthcare and tools firms are also updating guidance this earnings season.
